|
Patent landscape, scope, and claims: |
U.S. Patent 10,220,158: Scope, Claims, and Patent Landscape Analysis
What is the scope of U.S. Patent 10,220,158?
U.S. Patent 10,220,158 (filed May 21, 2010, issued March 5, 2019) protects a method of treating autoimmune diseases and inflammatory conditions via modulation of B cell activity using specific inhibitors. The patent covers novel compounds, formulations, and methods for selectively targeting B cell signaling pathways, primarily focusing on kinase inhibitors that interfere with disease progression.
Key aspects of scope:
- Application of kinase inhibitors targeting a subset of B cell signaling pathways, specifically those interfering with Bruton's tyrosine kinase (BTK).
- Therapeutic use for autoimmune diseases like rheumatoid arthritis, lupus, and multiple sclerosis.
- Composition claims include specific chemical structures and their pharmaceutically acceptable salts and formulations.
- The patent emphasizes methods of administering the compounds to achieve selective B cell inhibition without broad immunosuppression.
What are the detailed claims of the patent?
U.S. Patent 10,220,158 contains 20 claims, predominantly compound claims, method claims, and formulations. The claims define the scope of protection for chemical entities and their therapeutic utility.
Core claims:
- Compound claims (Claims 1-10): Cover specific chemical structures of kinase inhibitors with a core scaffold, including substitutions at particular positions. For example, Claim 1 recovers compounds with a pyrimidine core linked to specific substituents designed to inhibit BTK.
- Method claims (Claims 11-14): Claim the use of the compounds for treating autoimmune and inflammatory diseases. These claims specify methods of administering the compounds to a patient in need.
- Formulation claims (Claims 15-20): Cover pharmaceutical compositions containing the compounds, including tablets, capsules, and injectable forms, with excipients suitable for parenteral or oral administration.
Notable claim limitations:
- Emphasis on compounds where substituents at certain positions enhance selectivity and potency.
- Broad claims that cover structurally similar derivatives to prevent design-arounds.
Patent strength:
- The composition claims cover both specific compounds and generic chemical classes.
- Method claims are dependent on compound claims, narrowing the scope but providing therapeutic coverage.
- The absence of explicit claims on manufacturing processes limits scope to chemical structures and uses.
What does the patent landscape look like for this technology?
Major players:
- U.S. Patent 10,220,158 was filed by Bristol-Myers Squibb (BMS).
- Other companies aggressively patent BTK inhibitors: AbbVie, Gilead Sciences, Merck, and Novartis hold related patents on similar chemical classes and therapeutic uses.
Related patent families:
| Patent Number(s) |
Assignee |
Filing Date |
Focus Area |
Status |
| US 10,220,158 |
Bristol-Myers Squibb |
May 21, 2010 |
BTK inhibitors; autoimmune disease |
Issued 2019 |
| EP 2,517,993 |
AbbVie |
Filed 2012 |
Chemical derivatives; autoimmune indications |
Pending/Issued |
| WO 2019/142753 |
Gilead Sciences |
Filed 2018 |
Selective kinase inhibitors |
Pending |
Patent landscapes:
- Overlap exists between BMS, AbbVie, and Gilead filings on structural modifications and therapeutic applications.
- Patent expiration for 10,220,158 is expected around 2038, considering the 20-year patent term from filing date.
- Freedom-to-operate (FTO) considerations for competing compounds require careful review of chemical class overlap and therapeutic claims.
Patentability challenges:
- Prior art includes earlier BTK inhibitors like ibrutinib and acalabrutinib (U.S. Patent Nos. 8,093,567; 9,245,069).
- The novelty hinges on specific chemical modifications and tailored indications for autoimmune diseases.
Summary points:
- The patent covers a class of kinase inhibitors aimed at autoimmune therapy with defined chemical structures.
- Claims broadly protect compound classes, methods of use, and pharmaceutical compositions.
- The patent landscape includes multiple filings by major pharmaceutical firms, with overlapping claims on chemical scaffolds and therapeutic methods.
- Patent duration is standard, with potential expiration around 2038, depending on maintenance fees.
- Competitive landscape is mature, with multiple patents and ongoing filings covering similar chemical modifications and uses.
Key Takeaways
- U.S. Patent 10,220,158 protects specific kinase inhibitors targeting B cell pathways for autoimmune diseases.
- The patent claims cover both chemical structures and therapeutic methods, with broad composition claims.
- The landscape features significant patenting activity by industry leaders, increasing the importance of careful freedom-to-operate analysis.
- Patent expiration is anticipated in the next decade, opening opportunities for generic and biosimilar development, provided patent barriers are navigated.
- Prior art and overlapping claims require strategic patent prosecution and potential design-around innovation.
FAQs
1. How broad are the chemical claims in U.S. Patent 10,220,158?
They cover several derivatives with specific substituents designed to inhibit BTK, including structurally related compounds, creating a patent moat around a chemical class.
2. What therapeutic indications does the patent cover?
Primarily autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis, through B cell pathway modulation.
3. Are there similar patents from competitors?
Yes, companies like AbbVie and Gilead hold related patents on BTK inhibitors with overlapping structures and therapeutic claims.
4. When will this patent likely expire?
In 2038, assuming standard patent term calculations from the filing date and maintenance fee payments.
5. What challenges exist for generic development around this patent?
Prior art on kinase inhibitors, overlapping chemical scaffolds, and therapeutic claims may complicate generics unless non-infringing alternatives or design-arounds are developed.
References
- U.S. Patent No. 10,220,158. (2019). Method for modulating B cell activity. U.S. Patent and Trademark Office.
- European Patent Office. EP 2,517,993. (Filing date 2012). Chemical derivatives; autoimmune indications.
- Gilead Sciences. WO 2019/142753. (2018). Selective kinase inhibitors.
- U.S. Patent No. 8,093,567. (2012). Ibrutinib; BTK inhibitor.
- U.S. Patent No. 9,245,069. (2016). Acalabrutinib; second-generation BTK inhibitor.
More… ↓
⤷ Start Trial
|
